|
WO2021043771A1
|
|
Formulations and treatment methods
|
|
WO2020240017A1
|
|
Lipid-controlled release compositions
|
|
WO2020240018A1
|
|
Administration device & regime
|
|
GB202003998D0
|
|
PED5 modulator formulations
|
|
GB201903889D0
|
|
PDE5 modulator formulations
|
|
GB201815215D0
|
|
Composition and use
|
|
GB201805191D0
|
|
Compositions
|
|
GB201804544D0
|
|
PDE5 Modulator formulations
|
|
GB201804545D0
|
|
Formulations
|
|
EP3518978A1
|
|
Mixtures and formulations comprising an alkyl ammonium edta salt
|
|
KR20190083645A
|
|
Prostaglandin analog preparation
|
|
GB201621277D0
|
|
Formulations
|
|
GB201616366D0
|
|
Formulations
|
|
GB201615754D0
|
|
Formulations
|
|
EA033590B1
|
|
Controlled-release formulations
|
|
AU2015227534A1
|
|
Peptide slow-release formulations
|
|
GB201516554D0
|
|
Controlled-release formulations
|
|
GB201419091D0
|
|
Formulations
|
|
US2014186279A1
|
|
Topical bioadhesive formulations
|
|
AU2013294915A1
|
|
Opioid formulations
|
